Number of the records: 1
Bioactive Natural Products
- 1.
SYSNO ASEP 0564409 Document Type M - Monograph Chapter R&D Document Type Monograph Chapter Title Biosynthesis of polyunsaturated fatty acids by metabolic engineering of yeast Yarrowia lipolytica Author(s) Palyzová, Andrea (MBU-M) RID, ORCID
Spížek, Jaroslav (MBU-M)
Vítová, Milada (MBU-M) RID, ORCID
Řezanka, Tomáš (MBU-M) ORCIDSource Title Bioactive Natural Products, Studies in Natural Products Chemistry. - Amsterdam : Elsevier B.V., 2022 / Atta-ur-Rahman - ISBN 978-0-323-91099-6 Pages s. 197-223 Number of pages 27 s. Number of pages 481 Publication form Print - P Language eng - English Country NL - Netherlands Keywords Yeast ; Yarrowia lipolytica ; Polyunsaturated fatty acids ; Genetically modified ; biosynthesis Subject RIV EE - Microbiology, Virology OECD category Microbiology Institutional support MBU-M - RVO:61388971 Annotation Metabolic engineering describes the involvement of primary metabolism in the overproduction of native and atypical metabolites, including nutraceuticals—compounds of great interest due to their health-promoting or disease-preventing properties—thus overcoming limitations of traditional low-yield extractions of natural materials or of complex chemical syntheses.
Omega-3 fatty acids, all cis-5,8,11,14,17-eicosapentaenoic (C20:5, EPA), and all-cis-4,7,10,13,16,19-docosahexaenoic (C22:6, DHA) acids provide great benefits in improving human health in adults and developing infants. Currently, the main source of EPA and DHA is fish oil, and microalgae are also used as a secondary source of DHA. However, because of the high demand for EPA and DHA, many synthetic methods have been developed for producing these and other ω-3 fatty acids, including metabolically engineered strains of oleaginous yeasts, especially Yarrowia lipolytica. This review describes current metabolic engineering strategies used in the manufacture of some nutraceuticals, especially high levels of polyunsaturated fatty acids (PUFAs).Workplace Institute of Microbiology Contact Eliška Spurná, eliska.spurna@biomed.cas.cz, Tel.: 241 062 231 Year of Publishing 2023 Electronic address https://www.sciencedirect.com/science/article/abs/pii/B9780323910996000074
Number of the records: 1